Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib

Imatinib (IM) treatment is one of the standards of care for chronic phase (CP) chronic myeloid leukemia (CML). Its generic form is currently widely available as a cost-effective frontline treatment [1]. Although IM treatment has improved outcomes for CML patients, resulting in a 6-year progression-free survival of 93% [2], patients who experience treatment failure at milestones are at increased risk of disease progression to accelerated phase (AP), blast phase (BP), and death due to CML [3 –6].

Source: Leukemia Research - June 7, 2018 Category: Hematology Authors: Sung-Eun Lee, Soo-Young Choi, Soo-Hyun Kim, Saengsuree Jootar, Hyeoung-Joon Kim, Sang-Kyun Sohn, Joon Seong Park, Sung-Hyun Kim, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim Tags: Research paper Source Type: research